Agent
Zerlasiran (SLN360)
Status Phase 2 complete; phase 3 outcomes trial awaits a partner
A GalNAc siRNA against LPA that lowered Lp(a) by up to 98 percent after single doses (APOLLO, JAMA 2022) and by more than 80 percent time-averaged over 36 weeks at 300 to 450 mg every 16 to 24 weeks (ALPACAR, JAMA 2024). Silence Therapeutics has said it will only start the phase 3 cardiovascular outcomes study once a partner is secured.
Milestones. APOLLO (Nissen, JAMA 2022, ACC.22); single- and multiple-dose study in ASCVD (JAMA 2024); ALPACAR (JAMA 2024, AHA 2024).
RNA therapeuticssiRNAzerlasiran
Page updated 17 August 2026.